← Structure Therapeutics Inc.
| Annual Trend | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| Operating Revenue | — | $0 | $0 | $0 | $0 | $0 | |
| Net Interest Income | — | $1.3m |
$13.4m
+965.31%
|
$36.0m
+168.93%
|
$35.9m
-0.39%
|
$43.7m
+21.75%
|
|
| Research And Development | — | $36.2m | $70.1m | $108.8m | $225.3m | $294.2m | |
| General and Administrative Expense | — | $16.4m | $32.7m | $49.4m | $61.6m | $73.8m | |
| Operating Expenses | — | $52.6m | $102.8m | $158.2m | $176.6m | $268.1m | |
| Operating Income (Loss) | — | ($52.6m) |
($102.8m)
-95.53%
|
($158.2m)
-53.96%
|
($176.6m)
-11.59%
|
($268.1m)
-51.82%
|
|
| Net Non Operating Interest Income Expense | — | $1.3m | $13.4m | $36.0m | $35.9m | $43.7m | |
| Gain On Sale Of PPE | — | — | $0 | $0 | $10.2m | $10.2m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | ($44.3m) | ($79.9m) | ($113.1m) | ($144.1m) | ($214.1m) | |
| Pre-Tax Income | — | ($51.3m) | ($89.4m) | ($122.2m) | ($140.7m) | ($214.1m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | ($51.3m) | ($89.4m) | ($122.2m) | ($140.7m) | ($214.1m) | |
| Current Income Tax Expense (Benefit) | — | $77k | $222k | $328k | $436k | $702k | |
| Income Tax Expense (Benefit) | — | $17k | $236k | $310k | $515k | $702k | |
| Net Income From Continuing And Discontinued Operation | — | ($51.3m) | ($89.6m) | ($122.5m) | ($141.2m) | ($214.8m) | |
| Otherunder Preferred Stock Dividend | $3.8m | $1.5m | $0 | — | — | — | |
| Preferred Stock Dividends | $3.8m | $1.5m | — | — | — | $1.5m | |
| Earnings Per Share, Basic | — | ($5.51) | ($0.81) | ($0.78) | ($0.80) | ($3.03) | |
| Earnings Per Share, Diluted | — | ($5.51) | ($0.81) | ($0.78) | ($0.80) | ($3.03) | |
| Weighted Average Number of Shares Outstanding, Basic | — | 9.6m | 110.2m | 157.9m | 177.6m | 66.7m | |
| Basic Average Shares | — | $38.2m | $36.7m | $57.3m | $70.8m | $66.7m | |
| Diluted Average Shares | — | $38.2m | $36.7m | $57.3m | $70.8m | $66.7m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | 9.6m | 110.2m | 157.9m | 177.6m | 66.7m | |
| Additional Financial Items | |||||||
| Diluted EPS | — | ($1.38) | ($2.43) | ($2.14) | ($1.99) | ($3.03) | |
| Diluted NI Availto Com Stockholders | — | ($52.8m) | ($89.6m) | ($122.5m) | ($141.2m) | ($214.8m) | |
| Minority Interests | ($2.0m) | $0 | — | — | — | $0 | |
| Normalized EBITDA | — | ($52.3m) | ($102.5m) | ($157.2m) | ($195.7m) | ($266.2m) | |
| Normalized Income | — | ($51.3m) | ($89.6m) | ($122.5m) | ($149.3m) | ($221.0m) | |
| Other Gand A | — | $16.4m | $32.7m | $49.4m | $61.6m | — | |
| Reconciled Depreciation | — | $277k | $295k | $992k | $1.3m | $1.9m | |
| Selling General And Administration | — | $16.4m | $32.7m | $49.4m | $61.6m | — | |
| Special Income Charges | — | — | $0 | $0 | $10.2m | $10.2m | |
| Tax Effect Of Unusual Items | — | $0 | $0 | $0 | $2.2m | $4.1m | |
| Tax Provision | — | $17k | $236k | $310k | $515k | $702k | |
| Tax Rate For Calcs | — | $0 | $0 | $0 | $0 | $0 | |
| Total Unusual Items | — | — | $0 | $0 | $10.2m | $10.2m | |
| Total Expenses | — | $52.6m | $102.8m | $158.2m | $186.8m | $268.1m | |
| Total Other Finance Cost | — | ($1.3m) | ($13.4m) | ($36.0m) | ($35.9m) | ($43.7m) |